Literature DB >> 8328782

Efficacy of clarithromycin for treatment of experimental Lyme disease in vivo.

J Alder1, M Mitten, K Jarvis, P Gupta, J Clement.   

Abstract

Clarithromycin provided effective therapy against arthritis induced by Borrelia burgdorferi infection in the hamster. In vitro, clarithromycin was at least 1 log more potent than tetracycline against two isolates of B. burgdorferi from human sources, as measured by MICs and 50% inhibitory concentrations. Clarithromycin was effective in preventing the onset of B. burgdorferi-induced arthritis, as determined by several parameters of paw swelling. When administered after the onset of arthritis, clarithromycin therapy reduced the degree of swelling and decreased recovery time. These results suggest that clarithromycin has potential as an effective therapy for Lyme disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8328782      PMCID: PMC187961          DOI: 10.1128/AAC.37.6.1329

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  23 in total

Review 1.  Lyme disease.

Authors:  S R Buchstein; P Gardner
Journal:  Infect Dis Clin North Am       Date:  1991-03       Impact factor: 5.982

2.  Comparative in vitro and in vivo susceptibilities of the Lyme disease spirochete Borrelia burgdorferi to cefuroxime and other antimicrobial agents.

Authors:  R C Johnson; C B Kodner; P J Jurkovich; J J Collins
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

3.  Ceftriaxone as effective therapy in refractory Lyme disease.

Authors:  R J Dattwyler; J J Halperin; H Pass; B J Luft
Journal:  J Infect Dis       Date:  1987-06       Impact factor: 5.226

4.  The spirochetal etiology of Lyme disease.

Authors:  A C Steere; R L Grodzicki; A N Kornblatt; J E Craft; A G Barbour; W Burgdorfer; G P Schmid; E Johnson; S E Malawista
Journal:  N Engl J Med       Date:  1983-03-31       Impact factor: 91.245

5.  The early clinical manifestations of Lyme disease.

Authors:  A C Steere; N H Bartenhagen; J E Craft; G J Hutchinson; J H Newman; D W Rahn; L H Sigal; P N Spieler; K S Stenn; S E Malawista
Journal:  Ann Intern Med       Date:  1983-07       Impact factor: 25.391

Review 6.  Lyme disease.

Authors:  E A Goldings; J Jericho
Journal:  Clin Rheum Dis       Date:  1986-08

7.  In vitro and in vivo susceptibility of the Lyme disease spirochete, Borrelia burgdorferi, to four antimicrobial agents.

Authors:  R C Johnson; C Kodner; M Russell
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

8.  In vitro and in vivo susceptibility of Borrelia burgdorferi.

Authors:  V P Mursic; B Wilske; G Schierz; M Holmburger; E Süss
Journal:  Eur J Clin Microbiol       Date:  1987-08       Impact factor: 3.267

9.  Susceptibility of the Lyme disease spirochete to seven antimicrobial agents.

Authors:  S E Johnson; G C Klein; G P Schmid; J C Feeley
Journal:  Yale J Biol Med       Date:  1984 Jul-Aug

10.  Isolation and cultivation of Lyme disease spirochetes.

Authors:  A G Barbour
Journal:  Yale J Biol Med       Date:  1984 Jul-Aug
View more
  4 in total

Review 1.  Evidence assessments and guideline recommendations in Lyme disease: the clinical management of known tick bites, erythema migrans rashes and persistent disease.

Authors:  Daniel J Cameron; Lorraine B Johnson; Elizabeth L Maloney
Journal:  Expert Rev Anti Infect Ther       Date:  2014-07-30       Impact factor: 5.091

Review 2.  Antimicrobial susceptibility of Borrelia burgdorferi sensu lato: what we know, what we don't know, and what we need to know.

Authors:  Klaus-Peter Hunfeld; Volker Brade
Journal:  Wien Klin Wochenschr       Date:  2006-11       Impact factor: 1.704

Review 3.  Choosing the right macrolide antibiotic. A guide to selection.

Authors:  L Charles; J Segreti
Journal:  Drugs       Date:  1997-03       Impact factor: 9.546

4.  Clarithromycin in treatment of early Lyme disease: a pilot study.

Authors:  R J Dattwyler; E Grunwaldt; B J Luft
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.